Shattuck Labs Advances SL-325 Program Amid Financial Progress

Shattuck Labs, Inc. ( (STTK) ) has released its Q1 earnings. Here is a breakdown of the information Shattuck Labs, Inc. presented to its investors.

Shattuck Labs, Inc. is a biotechnology company focused on developing novel therapeutics targeting tumor necrosis factor superfamily receptors to treat inflammatory and immune-mediated diseases. The company operates in the biotechnology sector and is known for its innovative approach to drug development.

In its first-quarter 2025 earnings report, Shattuck Labs highlighted the advancement of its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of approximately $60.9 million as of March 31, 2025, which is expected to fund operations into 2027.

Key financial metrics from the report include a reduction in research and development expenses to $9.9 million from $16.3 million in the same quarter of the previous year. General and administrative expenses also saw a slight decrease. The net loss for the quarter was $13.7 million, an improvement from the $18.5 million loss reported in the first quarter of 2024. The company continues to focus on advancing its lead product candidate, SL-325, a DR3 antagonist antibody for treating inflammatory bowel disease.

Shattuck Labs is progressing with its strategic initiatives, including the development of preclinical DR3-based bispecific antibodies and plans to nominate a lead bispecific candidate in 2025. The company has completed significant wind-down activities related to its discontinued oncology programs, aligning its focus on its core therapeutic areas.

Looking ahead, Shattuck Labs remains optimistic about its financial position and strategic direction, with plans to initiate a Phase 1 clinical trial for SL-325 in the third quarter of 2025. The management is confident in its ability to sustain operations and continue its research and development efforts well into the future.